Education
About Us
Working with TipRanks
Follow Us
Novabridge Biosciences (NBP)
:NBP
NBP Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
NBP FAQ
What was Novabridge Biosciences’s price range in the past 12 months?
Currently, no data Available
What is Novabridge Biosciences’s market cap?
Novabridge Biosciences’s market cap is $338.15M.
When is Novabridge Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Novabridge Biosciences’s earnings last quarter?
Currently, no data Available
Is Novabridge Biosciences overvalued?
According to Wall Street analysts Novabridge Biosciences’s price is currently Undervalued.
Does Novabridge Biosciences pay dividends?
Novabridge Biosciences does not currently pay dividends.
What is Novabridge Biosciences’s EPS estimate?
Novabridge Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novabridge Biosciences have?
Novabridge Biosciences has 115,119,490 shares outstanding.
What happened to Novabridge Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Novabridge Biosciences?
Currently, no hedge funds are holding shares in NBP
Company Description
Novabridge Biosciences
I-MAB (IMAB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The company is engaged in the development of innovative monoclonal antibodies and biologics, leveraging its integrated research and development capabilities. I-MAB aims to address unmet medical needs through its proprietary drug discovery and development platforms.
Ownership Overview
―
Insiders
0.06%
Mutual Funds
2.58% Other Institutional Investors
96.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---